688622 Guangzhou Hexin Instrument
- 18.41
- +0.17+0.93%
Guangzhou Hexin Instrument News
Hexin Instruments (688622.SH): Net loss of 15.0191,000 yuan in the first quarter
On April 29, Ge Longhui (688622.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 46.6031 million yuan, a year-on-year decrease of 18.12%; net profit attributable to shareholders of listed companies - 15.191,000 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 168.15,700 yuan; and basic earnings per share - 0.21 yuan.
Hexin Instruments (688622.SH): 2023 net profit - 96.106 million yuan
On April 25, Ge Longhui (688622.SH) released its 2023 annual report, achieving operating income of 366 million yuan, an increase of 30.66% over the previous year; net profit attributable to shareholders of listed companies - 96.106 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 111 million yuan, and basic earnings per share - 1.37 yuan.
Hexin Instrument (688622.SH): Various products are being deployed in the medical field and are expected to form relatively complete solutions in the medical field
Gelonghui, Feb. 29丨Hexin Instrument (688622.SH) recently said during a survey reception from institutional investors that the company is laying out a variety of products in the medical field and is expected to form a relatively complete solution in the medical field. Specifically, products that have obtained registration certificates include CMI series fully automatic microbial mass spectrometry testing systems; products that already have hardware products and are applying for registration certificates include triple quadrupole liquid mass spectrometers (LC-TQ series), etc.; new products being developed include next-generation trace element detection systems (ICP-MS series).
Guangzhou Hexin Instrument's Chief Financial Officer Resigns
Li Junfeng, chief financial officer of Guangzhou Hexin Instrument (SHA:688622), resigned due to personal reasons, according to a Saturday filing. Zhou Zhen, the chairman of the mass spectrometer manuf
Hexin Instruments (688622.SH): net loss of 887.14,700 yuan in 2023
Gelonghui, Feb. 25, 丨 Hexin Instrument (688622.SH) announced the 2023 Annual Results Report. In 2023, the company achieved operating income of 378 million yuan, an increase of 34.88% over the same period of the previous year; realized net profit attributable to owners of the parent company - 887.14,700 yuan; and realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss - 103 million yuan.
Li Junfeng, financial director of Hexin Instruments (688622.SH), resigns
Zhitong Finance App News, Hexin Instruments (688622.SH) announced that Li Junfeng, the company's financial director, applied to the board of directors to resign as the company's financial director. After resigning, he will no longer hold any position in the company.
Hexin Instruments (688622.SH) issued a forecast loss. The net loss is expected to be 80 million yuan to 96 million yuan in 2023
Hexin Instruments (688622.SH) issued an announcement. The company expects to be owned by the parent company in 2023...
Guangzhou Hexin Instrument Co.,Ltd. (SHSE:688622) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Guangzhou Hexin Instrument Co.,Ltd. (SHSE:688622) shareholders won't be pleased to see that the share price has had a very rough month, dropping 26% and undoing the prior period's positive performance
Hexin Instrument (688622.SH): At present, it has basically achieved full coverage of mainstream mass spectrometry technology routes
Gelonghui, January 26丨Hexin Instrument (688622.SH) recently said during a survey reception from institutional investors that with the company's accelerated investment in R&D in recent years, the company has now basically achieved full coverage of mainstream mass spectrometry technology routes, and has also basically touched on various application fields. The company's next research and development goals are mainly continuous product upgrades and iterations to improve performance and product quality, and expand product application areas.
[BT Financial Report Momentary Analysis] Hexin Instruments 2023 Quarterly Report: Business Development and Financial Challenges Driven by Innovation
As a high-tech enterprise focusing on mass spectrometer R&D, production, sales and technical services, Hexin Instruments (stock code: 688622) demonstrated its brand advantages in the field of atmospheric environment monitoring and active expansion into new fields such as healthcare, laboratory analysis, and life science in the 2023 three-quarter report. The company's newly released quadrupole time-of-flight liquid-mass spectrometer (LC-QTOF 7000) further demonstrates its ability to continue to innovate in mass spectrometry technology. In terms of assets and liabilities, Hexin Instrument's total assets increased from 972 million yuan at the end of the previous year to 1,094 million yuan at the end of the reporting period
Hexin Instrument (688622.SH): The company has successfully expanded new business areas in recent years and orders have continued to grow
Gelonghui, January 2丨Hexin Instrument (688622.SH) disclosed a record sheet of investor relations activities, showing that the company has been expanding smoothly in new business areas in recent years, orders have continued to grow, and healthcare, laboratories and other fields have begun to occupy a certain market share. Looking forward to the future, the company hopes to gradually increase the share of non-environmental protection businesses and get rid of the environmental monitoring sector's dependence on government procurement.
Hexin Instrument (688622.SH): Kunshan Guoke's holdings reduction plan has not been reduced at the end of the period
Hexin Instruments (688622.SH) issued an announcement from June 28, 2023 to December 2, 2023...
Hexin Instruments (688622.SH) plans to sign a technology development contract with Max Research Institute
Hexin Instruments (688622.SH) issued an announcement. The company and related party, Guangdong Max Scientific Instrument Innovation Research Institute (...
Hexin Instruments (688622.SH): ICP-MS series products currently under development have made good progress in localizing components
Gelonghui, December 11|Hexin Instruments (688622.SH) stated on the investor interactive platform that the company has always been committed to localizing all product components and has carried this concept throughout the product development and production process. Good progress has been made in localizing components for the ICP-MS series products currently being developed. In the future, we will continue to increase cooperation with local enterprises upstream in the industrial chain to promote comprehensive localization of components.
Hexin Instruments (688622.SH): Transfer of assets to wholly-owned subsidiaries
Gelonghui (688622.SH) announced on December 1丨Hexin Instruments () announced that in order to integrate the company's business and assets and improve management efficiency, the company transferred the relevant assets, personnel, rights and obligations involved in the operation and operation and maintenance business related to the existing environmental monitoring field to Hexin Technology, a wholly-owned subsidiary, and authorized management to handle specific matters related to asset transfer. The base date for this transfer is November 30, 2023, and the net book value is RMB 25.417,800. For asset changes that occurred between the transfer reference date and the actual transfer date, the company will adjust according to the actual situation, and the final transfer amount of assets will be actual
Hexin Instruments (688622.SH): Net loss of 54.9982 million yuan in the first three quarters
On October 30, Gelonghui (688622.SH) released its report for the first three quarters of 2023. During the reporting period, it achieved operating income of 249 million yuan, an increase of 65.30% over the previous year; net loss attributable to shareholders of listed companies of 54.9982 million yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 66.5075 million yuan; basic earnings per share - 0.79 yuan.
Hexin Instruments (688622.SH): Currently, products that have obtained registration certificates in the medical field include the CMI series fully automated microbial mass spectrometry detection system
Glonghui, Oct. 19 | Hexin Instrument (688622.SH) Investor Relations Activity Record Form shows that the company's current certified products in the medical field include the CMI series fully automated microbial mass spectrometry testing system; the products that already have hardware products and are currently applying for registration certificates include the NucMass series fully automatic nucleic acid mass spectrometry detection system and the LC-TQ series triple quadrupole liquid quality combination instrument (used for neonatal genetic metabolic disease screening, vitamin analysis, etc.); New products being developed include a new generation of trace element detection systems (ICP-MS series).
Hexin Instruments (688622.SH): Actively expanding the application of artificial intelligence algorithms, big data and other technologies to improve the level of product intelligence
Glonghui, Oct. 11 | Hexin Instruments (688622.SH) said on the investor interactive platform that the company is fully aware that the development of artificial intelligence technology is an industry trend. Currently, it is actively expanding the application of artificial intelligence algorithms, big data and other technologies to improve the level of product intelligence, and is exploring the development of smart laboratory solutions and the intelligence of various products.
Hexin Instrument (688622.SH): Currently, the company's new businesses in the medical and laboratory fields are developing smoothly
Glonghui, September 20 | Hexin Instruments (688622.SH) said at the performance briefing that the new medical and laboratory business areas are the company's key expansion direction in the short to medium term, and are also an important growth point for future performance. Currently, the company's new businesses in the medical and laboratory fields are developing smoothly. With support from national policies, orderly business development and gradual market development, the company's orders and revenue in new business fields such as medical care and laboratories are expected to gradually increase.
Hexin Instruments (688622.SH): 875,000 restricted shares will be listed and distributed from September 13
Glonghui September 5: Hexin Instruments (688622.SH) announced that the sale restrictions have been lifted and the number of tradable shares applied for listing is 875,000 shares, which will be listed and distributed from September 13, 2023.
Analysis
Price Target
No Data
